hotspot -WSS

hotspot

author：hotspot 2025-09-30 17:45:30 - browse：43

This image provided by Amylyx Pharmaceuticals shows the drug Relyvrio. The maker of a much-debated drug for Lou Gehrig’s disease said Friday, March 8, 2024 its therapy failed to help patients in a large follow-up study, but stopped short of committing to follow through on a prior pledge to pull the drug from the U.S. market. — Relyvrio, an ALS drug made by Amylyx Pharmaceuticals, failed to beat placebo in a key clinical trial. Amylyx Pharmaceuticals via AP

The latest disappointment in amyotrophic lateral sclerosis research brought crushing news for patients and physicians, forcing the community to consider just what to do with an approved medicine that doesn’t appear to work.

Amylyx Pharmaceuticals’ announcement Friday that its drug, marketed as Relyvrio, failed to beat placebo in a pivotal study marks “a sad day for us, but we have to believe the data,” said Mary Catherine Collet, an ALS advocate. “These are hard scientific facts that we have to face, and I appreciate that they’re not trying to spin us like some cheerleading practice.”

The question now is whether Relyvrio, approved in 2022, should be removed from the market entirely — and whether the Food and Drug Administration made a mistake by authorizing it in the first place. After years of pressure from patient advocates, the agency has taken a more flexible approach to medicines for devastating, incurable diseases like ALS. But the case of Relyvrio, which made $381 million in sales and $49 million in profit for Amylyx last year, has underlined questions about the limits of regulatory leniency.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Activists slam private health insurers over coverage restrictions
Next article： AbbVie buys Immunogen, maker of targeted cancer drugs, for $10B

leisure time

explore

WSS

Radiology is caught between AI's potential and concern for patients

Americans' trust in science, scientist continues decline: Report

Chronically ill young patients struggle to find fertility info

Americans' trust in science, scientist continues decline: Report

Burning questions for the 2024 JPM Healthcare Conference

Americans' trust in science, scientist continues decline: Report

explore

hotspot

focus

Continuity nursing helped my family in our darkest PICU moments

Videos point to link between seizures and unexplained toddler deaths

Continuity nursing helped my family in our darkest PICU moments

Supreme Court wrestles with OxyContin maker's bankruptcy deal

Moonlake's readout produced a cash windfall. Risks remain

Congenital heart disease patients face new threat of heart failure

Guidelines to prevent youth baseball injuries need more muscle

After sickle

FDA approval of Sarepta Duchenne genetic therapy gives me hope

U.K. sequencing study surfaces new findings about tumor DNA

hotspot

SCOTUS to consider access to abortion pill mifepristone

In diabetes hearing, Sanders takes on a new foe: food makers

Radiology is caught between AI's potential and concern for patients

U.K. sequencing study surfaces new findings about tumor DNA

White House finalizes ITC's import ban of latest Apple Watches

AbbVie buys Immunogen, maker of targeted cancer drugs, for $10B

Wikipedia

leisure time

explore

focus